Data from the phase 3 METRIC study comparing trametinib vs. chemotherapy in V600E/K mutated melanoma revealed clear superiority of MEK inhibition with an ORR of 24% for trametinib vs. 7% for chemotherapy and median PFS of 4.8 months vs. 1.5 months, respectively [40••]. This evidence concerns the gene MAP2K7 and melanoma.